Login
Login     |     Register     |     Recover Username/Password

General Investing

Las Vegas Sands (LVS), Wynn Resorts (WYNN) and MGM Resorts (MGM) Reap Rewards from Macau Exposure

December 11, 2012

Las Vegas Sands (LVS), Wynn Resorts (WYNN) and MGM Resorts (MGM) provide opportunities for investors looking to participate in Macau gaming, says Harry C. Curtis, Managing Director and Senior Analyst at Nomura Securities International, Inc. He says he expects growth the Macau market to grow in 2013 with increased profit margins.

“Notably, the gaming volumes and growth have continued to be very strong in the mass segment, and the mass segment is important because it’s got a 35% margin as opposed to 12% margin for the VIP business. But the VIP business has been stuck in neutral. Our sense in 2013 is that there should be mid-single digit growth in the VIP segment as the Chinese economy reaccelerates, and that the mass segment will continue to grow at about 20%,” Curtis said.

Curtis says his favorite stock is Las Vegas Sands. “That’s mainly an Asian gambling company, generating 75% or 80% of its EBITDA between Singapore and Macau. They just raised their dividend and they’re generating $2 billion to $2.5 billion of free cash flow annually, over and above their maintenance capex and dividend requirement. They could return even more capital to shareholders if they wanted to,” he said.

“We also like Wynn, which is a free cash flow story. The stock’s yielding nearly 4%. And at some point, investors are going to begin giving them credit for a new casino under construction in Macau,” he said.

Curtis also likes MGM, which has exposure to the Macau gaming story. “At around $9.50 a share, it’s really not getting any credit for the value of its cash flows in Macau. All of the value ascribed to the equity is found in Macau, and there is really no value investors are according it in the U.S.,” he said.


TSWT - Subscribe now!

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Manager Interviews

TWST Newsletter

Weekly email with New In-Depth Interviews

Most Popular Interviews
Opportunities in Hepatitis C and Genomic Technologies
David Ferreiro

Published April 26, 2014 in Biotechnology and Pharmaceuticals

Buy ($75)
Investing in Health Care Innovation
Finny Kuruvilla

"We’re a faith-based and socially responsible investing firm"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
A Health Sciences Fund with a Long-Term Focus
Mark W. Oelschlager

"The fund is about $40 million in assets"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
High-Yield Canadian Power Companies
John McIlveen

Published May 14, 2013 in High-Yield Equity Securities

Buy ($75)
Most Popular Reports
Investing in Health Care

Published May 16, 2013

Topics Covered: Health Care - Electronic Health Record Adoption - Biotechnology and Pharmaceutical Investing - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Companies Valuation - Platform Interoperability and Data Analytics - HITECH Act Incentives - Affordable Care Act
Buy ($175)
Internet Services

Published May 10, 2013

Topics Covered: Increased Mobile Content Traffic - Chinese Online Monetization Trends - Internet Infrastructure and Services Consolidation - Social Networking Economics -
Buy ($175)
Investing Strategies

Published May 10, 2013

Topics Covered: Investing in Financial Services - Long-Term Investing - Large Cap Investing - Value Investing - High Quality Companies - Bottom-up Investing - All-Cap Growth Investing - Investing in Emerging Markets
Buy ($175)
Top Company Interviews
TWST
Register for a Free Account to gain greater access to The Wall Street Transcript right now